Impact of Weight on Clinical Outcomes of Edoxaban Therapy in Atrial Fibrillation Patients Included in the ETNA-AF-Europe Registry.
Boriani, Giuseppe De Caterina, Raffaele Manu, Marius Constantin Souza, José Pecen, Ladislav
Boriani, Giuseppe
De Caterina, Raffaele
Manu, Marius Constantin
Souza, José
Pecen, Ladislav
Citations
Altmetric:
Affiliation
University of Modena and Reggio Emilia; University of Pisa; University Heart and Vascular Centre UKE Hamburg; Sandwell and West Birmingham NHS Trust
Other Contributors
Publication date
2021-06-29
Subject
Collections
Research Projects
Organizational Units
Journal Issue
Abstract
Patients weighing ≤60 kg were older, more frail and had a higher CHA2DS2-VASc score vs. the other weight groups. The rates of stroke/systemic embolism, major bleeding and ICH were low at 1 year (0.82, 1.05 and 0.24%/year), with no significant differences among weight groups. The annualised event rates of all-cause death were 3.50%/year in the overall population. After adjustment for eGFR and CHA2DS2-VASc score, the risk of all-cause death was significantly higher in extreme weight groups vs. the reference group.
Citation
Boriani G, De Caterina R, Manu MC, Souza J, Pecen L, Kirchhof P. Impact of Weight on Clinical Outcomes of Edoxaban Therapy in Atrial Fibrillation Patients Included in the ETNA-AF-Europe Registry. J Clin Med. 2021 Jun 29;10(13):2879.
Type
Article